Genfit S.A. (FRA:XUP)

Market Cap	505.92M +186.4%
Revenue (ttm)	65.43M -7.4%
Net Income	-85.97M
EPS	-1.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	37.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	9.41
Previous Close	10.44
Day's Range	9.41 - 9.41
52-Week Range	3.01 - 11.26
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 188
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XUP

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error